Visual assessment of medial temporal lobe atrophy on r Interobserver reliability

Journal of Neurology 242, 557-560 DOI: 10.1007/bf00868807

Citation Report

#	Article	IF	CITATIONS
1	Medial temporal lobe atrophy in memory disorders. Journal of Neurology, 1997, 244, 175-181.	3.6	45
2	Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimer's Disease. European Neurology, 1998, 39, 16-25.	1.4	28
3	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of Neurology, 1999, 246, 477-485.	3.6	298
4	Clinical Value of Neuroimaging in the Diagnosis of Dementia Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. Molecular Imaging and Biology, 1999, 2, 119-130.	0.3	71
5	Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Research - Neuroimaging, 1999, 90, 193-199.	1.8	58
6	Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 630-635.	1.9	211
7	Structural neuroimaging of Alzheimer's disease and other dementias. Aging Clinical and Experimental Research, 2001, 13, 203-209.	2.9	15
8	Semantic knowledge and episodic memory for faces in semantic dementia Neuropsychology, 2001, 15, 101-114.	1.3	86
9	Clinical and Imaging Characteristics of Vascular Dementia in a Memory Clinic. , 0, , 219-228.		0
10	Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 165-173.	1.9	171
11	No Right to Speak? The Relationship between Object Naming and Semantic Impairment:Neuropsychological Evidence and a Computational Model. Journal of Cognitive Neuroscience, 2001, 13, 341-356.	2.3	344
12	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology, The, 2002, 1, 13-21.	10.2	337
13	Interrater Reliability among Epilepsy Centers: Multicenter Study of Epilepsy Surgery. Epilepsia, 2002, 43, 1396-1401.	5.1	35
14	Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. Neuropsychologia, 2003, 41, 1330-1344.	1.6	363
15	Prescription practices of diagnostic imaging in dementia: a survey of 47 Alzheimer's Centres in Northern Italy. International Journal of Geriatric Psychiatry, 2003, 18, 577-585.	2.7	8
16	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. NeuroImage, 2003, 18, 895-907.	4.2	388
17	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology, 2004, 63, 94-100.	1.1	307
18	The role of brain infarcts and hippocampal atrophy in subcortical ischaemic vascular dementia. Neurological Sciences, 2004, 25, 192-197.	1.9	36

τατιών Ρερώ

#	Article	IF	CITATIONS
19	Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1467-1469.	1.9	206
20	Pathological Aging of the Brain. Topics in Magnetic Resonance Imaging, 2004, 15, 369-389.	1.2	60
21	Visual Assessment of Atrophy on Magnetic Resonance Imaging in the Diagnosis of Pathologically Confirmed Young-Onset Dementias. Archives of Neurology, 2005, 62, 1410.	4.5	101
22	Neuroimaging Determinants of Cognitive Performances in Stroke Associated With Small Vessel Disease. Journal of Neuroimaging, 2005, 15, 129-137.	2.0	29
23	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1497-1500.	1.9	96
24	Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 304-307.	1.9	88
25	Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology, 2005, 64, 1040-1046.	1.1	158
26	Determinants of Prestroke Cognitive Impairment in Stroke Associated with Small Vessel Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 225-230.	1.5	28
27	Blood Pressure, White Matter Lesions and Medial Temporal Lobe Atrophy: Closing the Gap between Vascular Pathology and Alzheimer's Disease?. Dementia and Geriatric Cognitive Disorders, 2005, 20, 331-337.	1.5	23
28	Hemifacial spasm, neuralgia, and syncope due to cranial nerve compression in a patient with vertebral artery ectasia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1500-1500.	1.9	6
29	Multicenter assessment of reliability of cranial MRI. Neurobiology of Aging, 2006, 27, 1051-1059.	3.1	96
32	Diabetes and cognitive impairment. Journal of Neurology, 2006, 253, 477-482.	3.6	72
33	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. Archives of Neurology, 2007, 64, 108.	4.5	178
34	Role of imaging techniques in the diagnosis of dementia. British Journal of Radiology, 2007, 80, S71-S77.	2.2	117
35	Chapter 15 Advances in Neuroimaging. Blue Books of Neurology, 2007, 30, 381-410.	0.1	0
36	Heritability of Magnetic Resonance Imaging (MRI) Traits in Alzheimer Disease Cases and Their Siblings in the MIRAGE Study. Alzheimer Disease and Associated Disorders, 2007, 21, 85-91.	1.3	28
37	Neurological soft signs and cerebral measurements investigated by means of MRI in schizophrenic patients. Neuroscience Letters, 2007, 413, 82-87.	2.1	27
38	Blood-Brain Barrier Permeability Correlates with Medial Temporal Lobe Atrophy but Not with Amyloid-β Protein Transport across the Blood-Brain Barrier in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 241-245.	1.5	33

#	Article	IF	CITATIONS
39	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 2007, 14, e1-26.	3.3	499
40	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. Annals of the New York Academy of Sciences, 2007, 1097, 215-224.	3.8	27
42	Small vessel versus large vessel vascular dementia. Journal of Neurology, 2008, 255, 1644-1651.	3.6	55
43	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2008, 23, 387-392.	2.7	34
44	Magnetic Resonance Imaging Traits in Siblings Discordant for Alzheimer Disease. Journal of Neuroimaging, 2008, 18, 268-275.	2.0	21
45	Structural brain imaging in diabetes: A methodological perspective. European Journal of Pharmacology, 2008, 585, 208-218.	3.5	46
46	Difference of the hippocampal and white matter microalterations in MCI patients according to the severity of subcortical vascular changes: Neuropsychological correlates of diffusion tensor imaging. Clinical Neurology and Neurosurgery, 2008, 110, 552-561.	1.4	40
47	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39
48	Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 869-873.	1.9	42
49	Cerebrospinal Fluid/Serum IgG Index Is Correlated with Medial Temporal Lobe Atrophy in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 144-147.	1.5	12
50	Discrimination between Alzheimer Disease, Mild Cognitive Impairment, and Normal Aging by Using Automated Segmentation of the Hippocampus. Radiology, 2008, 248, 194-201.	7.3	233
51	A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer's Disease. Behavioural Neurology, 2009, 21, 13-19.	2.1	21
52	Education Attenuates the Effect of Medial Temporal Lobe Atrophy on Cognitive Function in Alzheimer's Disease: The MIRAGE Study. Journal of Alzheimer's Disease, 2009, 17, 855-862.	2.6	42
53	Longitudinal prognostic value of serum "free―copper in patients with Alzheimer disease. Neurology, 2009, 72, 50-55.	1.1	129
54	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64–Detector Row CT. Radiology, 2009, 253, 174-183.	7.3	121
55	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. Stroke, 2009, 40, 492-498.	2.0	118
56	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology, 2009, 73, 935-940.	1.1	70
57	Visual rating of the hippocampus in nonâ€demented elders: Does it measure hippocampal atrophy or other indices of brain atrophy? The SMARTâ€MR study. Hippocampus, 2009, 19, 1115-1122.	1.9	15

#	Article	IF	CITATIONS
58	Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study. Neuroradiology, 2009, 51, 363-371.	2.2	14
59	Medial temporal lobe atrophy in vascular dementia: Visual temporal lobe rating scale. Archives of Gerontology and Geriatrics, 2009, 48, 415-418.	3.0	12
60	Patients With Alzheimer Disease With Multiple Microbleeds. Stroke, 2009, 40, 3455-3460.	2.0	202
61	Progression of Mild Cognitive Impairment to Dementia. Stroke, 2009, 40, 1269-1274.	2.0	128
62	Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism and Related Disorders, 2009, 15, 88-93.	2.2	155
63	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. Cerebrovascular Diseases, 2009, 27, 336-344.	1.7	78
64	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. Cerebrovascular Diseases, 2009, 27, 384-391.	1.7	167
65	Multi-parametric classification of Alzheimer's disease and mild cognitive impairment: The impact of quantitative magnetization transfer MR imaging. NeuroImage, 2009, 48, 657-667.	4.2	35
66	Visual Rating System for Assessing Magnetic Resonance Images. Journal of Computer Assisted Tomography, 2009, 33, 73-78.	0.9	48
67	Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease. Journal of Neurology, 2010, 257, 839-842.	3.6	17
68	Magnetic resonance imaging of cerebral involutional changes in dogs as markers of aging: An innovative tool adapted from a human visual rating scale. Veterinary Journal, 2010, 186, 166-171.	1.7	22
69	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping, 2010, 31, 786-797.	3.6	91
70	Age-Related Changes in White Matter Lesions, Hippocampal Atrophy, and Cerebral Microbleeds in Healthy Subjects Without Major Cerebrovascular Risk Factors. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 302-309.	1.6	74
71	Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, e101-8.	0.8	61
72	Ceruloplasmin/Transferrin Ratio Changes in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	2.0	35
73	Visual assessment of posterior atrophy development of a MRI rating scale. European Radiology, 2011, 21, 2618-2625.	4.5	299
74	Atrophy: When too much atrophy is too little brain. Neuroradiology, 2011, 53, 133-139.	2.2	11
75	Incident lacunes influence cognitive decline. Neurology, 2011, 76, 1872-1878.	1.1	183

#	Article	IF	CITATIONS
76	Visual Rating versus Volumetry to Detect Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2011, 31, 371-378.	1.5	8
77	Minimal Atrophy of the Entorhinal Cortex and Hippocampus: Progression of Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2011, 31, 276-283.	1.5	30
78	White Matter Disease Independently Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease in a Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2011, 31, 431-434.	1.5	68
79	Identification of pure subcortical vascular dementia using ¹¹ C-Pittsburgh compound B. Neurology, 2011, 77, 18-25.	1.1	176
80	Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiologica, 2012, 53, 318-323.	1.1	35
81	Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. Acta Radiologica, 2012, 53, 573-579.	1.1	32
82	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging, 2012, 33, 627.e1-627.e12.	3.1	74
83	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1011.e1-1011.e9.	3.1	55
84	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology, 2012, 79, 763-769.	1.1	72
85	New visual rating system for medial temporal lobe atrophy: a simple diagnostic tool for routine examinations. Psychogeriatrics, 2012, 12, 88-92.	1.2	6
86	Structural Neuroimaging in Aging and Alzheimer's Disease. Neuroimaging Clinics of North America, 2012, 22, 33-55.	1.0	29
87	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. BMC Psychiatry, 2012, 12, 167.	2.6	40

88 Medial Temporal Atrophy and Memory Dysfunction in Poststroke Cognitive Impairment-No Dementia.

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATIONS
95	Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study. Alzheimer Disease and Associated Disorders, 2013, 27, 174-181.	1.3	22
96	Multiple Microbleeds are Related to Cerebral Network Disruptions in Patients with Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 211-221.	2.6	89
97	The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. Frontiers in Aging Neuroscience, 2013, 5, 47.	3.4	31
98	Comparison of Medial Temporal Measures between Binswanger's Disease and Alzheimer's Disease. PLoS ONE, 2014, 9, e86423.	2.5	9
99	Science to Practice: Translating Automated Brain MRI Volumetry in Alzheimer's Disease from Research to Routine Diagnostic Use in the Work-Up of Dementia. Frontiers in Neurology, 2014, 4, 216.	2.4	16
100	Prevalence of cortical superficial siderosis in a memory clinic population. Neurology, 2014, 82, 698-704.	1.1	71
101	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	9.0	140
102	Cerebral white matter disease is independently associated with BPSD in Alzheimer's disease. Journal of the Neurological Sciences, 2014, 337, 162-166.	0.6	15
103	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	1.2	30
104	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. European Radiology, 2014, 24, 397-404.	4.5	27
105	Cingulum Correlates of Cognitive Functions in Patients with Mild Cognitive Impairment and Early Alzheimer's Disease: A Diffusion Spectrum Imaging Study. Brain Topography, 2014, 27, 393-402.	1.8	52
106	Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease. Human Brain Mapping, 2014, 35, 3132-3142.	3.6	126
107	White Matter Hyperintensities andÂCognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. American Journal of Geriatric Psychiatry, 2014, 22, 157-166.	1.2	25
108	Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer's Disease. ACS Chemical Neuroscience, 2014, 5, 830-836.	3.5	90
109	White Matter Hyperintensities in Mild Cognitive Impairment: Clinical Impact of Location and Interaction with Lacunes and Medial Temporal Atrophy. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e365-e372.	1.6	13
110	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
111	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.	2.6	14
112	Neuropsychological and neuroimaging markers in prediction of cognitive impairment after ischemic stroke: a prospective follow-up study. Neuropsychiatric Disease and Treatment, 2015, 11, 2711.	2.2	15

#	Article	IF	CITATIONS
113	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27
114	Cognitive reserve and the risk for Alzheimer's disease: a longitudinal study. Neurobiology of Aging, 2015, 36, 592-600.	3.1	38
115	Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimer's Disease Neuroimaging Initiative. American Journal of Neuroradiology, 2015, 36, 653-660.	2.4	57
116	Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. International Journal of Geriatric Psychiatry, 2015, 30, 192-200.	2.7	30
117	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	2.6	18
118	The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study. Alzheimer's Research and Therapy, 2015, 7, 18.	6.2	10
119	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1225-1233.	1.9	114
120	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. American Journal of Geriatric Psychiatry, 2015, 23, 1056-1066.	1.2	26
121	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke, 2015, 46, 2661-2664.	2.0	73
122	Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease. European Journal of Neurology, 2015, 22, 150-155.	3.3	36
123	Structural Image Analysis of the Brain in Neuropsychology Using Magnetic Resonance Imaging (MRI) Techniques. Neuropsychology Review, 2015, 25, 224-249.	4.9	35
124	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. Korean Journal of Radiology, 2016, 17, 827.	3.4	61
125	Cerebral microbleeds in early Alzheimer's disease. Journal of Neurology, 2016, 263, 1961-1968.	3.6	37
126	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
127	Diagnostic Accuracy of MRI andÂAdditional [18F]FDG-PET forÂBehavioral Variant Frontotemporal Dementia in Patients withÂLate Onset Behavioral Changes. Journal of Alzheimer's Disease, 2016, 53, 1287-1297.	2.6	58
128	Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 377-389.	2.6	51
129	Can patients without early, prominent visual deficits still be diagnosed of posterior cortical atrophy?. Journal of the Neurological Sciences, 2016, 367, 26-31.	0.6	4
130	Cerebrospinal fluid volumetric MRI mapping as a simple measurement for evaluating brain atrophy. European Radiology, 2016, 26, 1254-1262.	4.5	14

#	Article	IF	Citations
131	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	2.7	137
133	Multimodality Imaging of Neurodegenerative Processes: Part 1, The Basics and Common Dementias. American Journal of Roentgenology, 2016, 207, 871-882.	2.2	15
134	Network-Based Substrate of Cognitive Reserve in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 421-430.	2.6	50
135	Brain perfusion in dementia with Lewy bodies and Alzheimer's disease: an arterial spin labeling MRI study on prodromal and mild dementia stages. Alzheimer's Research and Therapy, 2016, 8, 29.	6.2	45
136	Volumetric MRI as a Diagnostic Tool in Alzheimer's Disease. Methods in Pharmacology and Toxicology, 2016, , 181-198.	0.2	3
138	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders, 2016, 41, 16-26.	1.5	12
139	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	7.3	79
140	Visual rating method and tensor-based morphometry in the diagnosis of mild cognitive impairment and Alzheimer's disease: a comparative magnetic resonance imaging study. Acta Radiologica, 2016, 57, 348-355.	1.1	9
141	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	13.7	2,430
142	Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. JAMA Neurology, 2016, 73, 76.	9.0	60
143	The radiological diagnosis of frontotemporal dementia in everyday practice: an audit of reports, review of diagnostic criteria, and proposal for service improvement. Clinical Radiology, 2016, 71, 40-47.	1.1	8
144	The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study. European Radiology, 2016, 26, 1716-1722.	4.5	10
145	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 235-243.	1.9	89
146	A comparison of measurement methods of hippocampal atrophy rate for predicting Alzheimer's dementia in the Aberdeen Birth Cohort of 1936. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 31-39.	2.4	12
147	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.8	59
148	Memory is Not Enough: The Neurobiological Substrates of Dynamic Cognitive Reserve. Journal of Alzheimer's Disease, 2017, 58, 171-184.	2.6	17
149	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. Journal of Alzheimer's Disease, 2017, 56, 63-74.	2.6	32
150	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	3.1	60

#	Article	IF	CITATIONS
151	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	3.4	67
152	Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians. Journal of Alzheimer's Disease Reports, 2017, 1, 71-88.	2.2	18
153	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics DespiteÂMultidisciplinary Application ofÂtheÂFTDC Criteria. Journal of Alzheimer's Disease, 2017, 60, 959-975.	2.6	34
154	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	9.0	77
155	Damage to the Frontal Aslant Tract Accounts for Visuo-Constructive Deficits in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1015-1024.	2.6	13
156	Cortical Cerebral Microinfarcts on 3 Tesla MRI in Patients with Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 60, 1443-1450.	2.6	22
157	Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2017, 44, 45-54.	1.5	10
158	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using twoâ€dimensional phase ontrast magnetic resonance imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 76-83.	2.4	39
159	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiology of Aging, 2017, 57, 133-142.	3.1	91
160	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 531-540.	0.8	99
161	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. European Radiology, 2017, 27, 1169-1175.	4.5	97
162	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer's Research and Therapy, 2017, 9, 67.	6.2	45
163	A Pilot Study on Brain Plasticity of Functional Connectivity Modulated by Cognitive Training in Mild Alzheimer's Disease and Mild Cognitive Impairment. Brain Sciences, 2017, 7, 50.	2.3	37
164	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience, 2017, 9, 117.	3.4	71
165	Cerebral Microbleeds in Cerebrovascular and Neurodegenerative Diseases with Cognitive Impairments. Neuroscience and Behavioral Physiology, 2017, 47, 1078-1085.	0.4	5
166	Assessment of brain cortical atrophy in neurodegenerative as well as selected neurological disorders – assessment methods and significance in diagnosis. Neuropsychiatria I Neuropsychologia, 2017, 1, 20-29.	0.4	1
167	Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected normative data. European Radiology, 2018, 28, 1739-1747.	4.5	18
168	Findings from the Swedish Study on Familial Alzheimer's Disease Including the APP Swedish Double Mutation. Journal of Alzheimer's Disease, 2018, 64, S491-S496.	2.6	9

#	Article	IF	CITATIONS
169	T1―or T2â€weighted magnetic resonance imaging: what is the best choice to evaluate atrophy of the hippocampus?. European Journal of Neurology, 2018, 25, 775-781.	3.3	3
170	Microbleeds are associated with depressive symptoms in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 112-120.	2.4	7
171	Coronal CT is Comparable to MR Imaging in Aiding Diagnosis of Dementia in a Memory Clinic in Singapore. Alzheimer Disease and Associated Disorders, 2018, 32, 94-100.	1.3	6
172	Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. Journal of Neuroimaging, 2018, 28, 301-306.	2.0	8
173	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 23.	6.2	20
174	The Progressive Acalculia Presentation of Parietal Variant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 63, 941-948.	2.6	10
175	Retinal oxygen metabolism in patients with mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 340-345.	2.4	27
176	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	2.6	122
177	Longitudinal changes in the brain in mild cognitive impairment: a magnetic resonance imaging study using the visual rating method and tensor-based morphometry. Acta Radiologica, 2018, 59, 973-979.	1.1	3
178	Reduced glucose transporter-1 in brain derived circulating endothelial cells in mild Alzheimer's disease patients. Brain Research, 2018, 1678, 304-309.	2.2	20
179	Subjective Cognitive Decline Is Associated with Greater White Matter Hyperintensity Volume. Journal of Alzheimer's Disease, 2018, 66, 1283-1294.	2.6	47
180	Cognitive Profiles and Atrophy Ratings on MRI in Senior Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 384.	3.4	7
181	Early-Onset Alzheimer Disease (EOAD) With Aphasia: A Case Report. Frontiers in Psychiatry, 2018, 9, 469.	2.6	4
182	Toward <scp>MRI</scp> â€based wholeâ€brain health assessment: The brain atrophy and lesion index (<scp>BALI</scp>). Aging Medicine (Milton (N S W)), 2018, 1, 55-63.	2.1	13
183	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	6.2	48
184	Neuroimaging Characteristics of Small-Vessel Disease in Older Adults with Normal Cognition, Mild Cognitive Impairment, and Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 199-206.	1.3	13
185	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	6.2	21
186	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	2.6	228

#	Article	IF	CITATIONS
187	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	3.4	29
188	Automatic normative quantification of brain tissue volume to support the diagnosis of dementia: A clinical evaluation of diagnostic accuracy. NeuroImage: Clinical, 2018, 20, 374-379.	2.7	25
189	InÂvivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. Neurobiology of Aging, 2018, 72, 72-82.	3.1	58
190	Prevalence and association of syphilis reactivity in an Asian memory clinic population. International Journal of STD and AIDS, 2018, 29, 1368-1374.	1.1	2
191	Association between cerebral microbleeds and hypertension in the Swedish general population "Good Aging in Skåne―study. Journal of Clinical Hypertension, 2019, 21, 1099-1107.	2.0	14
192	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. Frontiers in Neuroscience, 2019, 13, 757.	2.8	22
193	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	3.7	5
194	Targeting ageâ€related differences in brain and cognition with multimodal imaging and connectome topography profiling. Human Brain Mapping, 2019, 40, 5213-5230.	3.6	33
195	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. Neuroradiology, 2019, 61, 397-404.	2.2	5
196	Cortical Microinfarcts and White Matter Connectivity in Memory Clinic Patients. Frontiers in Neurology, 2019, 10, 571.	2.4	8
197	Mutation Analysis of the Genes Linked to Early Onset Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2019, 69, 775-782.	2.6	7
198	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
199	Validation of an Magnetic Resonance Imaging Acquisition and Review Protocol for Alzheimer's Disease and Related Disorders. Canadian Association of Radiologists Journal, 2019, 70, 172-180.	2.0	2
200	Multiple Visual Rating Scales Based on Structural MRI and a Novel Prediction Model Combining Visual Rating Scales and Age Stratification in the Diagnosis of Alzheimer's Disease in the Chinese Population. Frontiers in Neurology, 2019, 10, 93.	2.4	13
201	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. Neurology, 2019, 92, e1558-e1566.	1.1	24
202	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	4.5	23
203	Juxtacortical lesions are associated with seizures in cerebral small vessel disease. Journal of Neurology, 2019, 266, 1230-1235.	3.6	7
204	Identifying brain changes related to cognitive aging using VBM and visual rating scales. NeuroImage: Clinical, 2019, 22, 101697.	2.7	10

ARTICLE IF CITATIONS Tablet-based sensorimotor home-training system for amnestic mild cognitive impairments in the 205 1.9 5 elderly: design of a randomised clinical trial. BMJ Open, 2019, 9, e028632. Clinical Use of Integrated Positron Emission Tomography-Magnetic Resonance Imaging for Dementia 206 1.2 9 Patients. Topics in Magnetic Resonance Imaging, 2019, 28, 299-310. Hypertension with Hyperhomocysteinemia Increases the Risk of Early Cognitive Impairment after 207 1.4 15 First-Ever Ischemic Stroke. European Neurology, 2019, 82, 75-85. Testing for the Myth of Cognitive Reserve: Are the Static and Dynamic Cognitive Reserve Indexes a 208 Representation of Different Reserve Warehouses?. Journal of Alzheimer's Disease, 2019, 72, 111-126. MRI-based evaluation of structural degeneration in the ageing brain: Pathophysiology and assessment. 209 10.9 41 Ageing Research Reviews, 2019, 49, 67-82. 7T MRI allows detection of disturbed cortical lamination of the medial temporal lobe in patients with Alzheimer's disease. NeuroImage: Clinical, 2019, 21, 101665. A comparative study: visual rating scores and the voxelâ€based specific regional analysis system for 211 Alzheimer's disease on magnetic resonance imaging among subjects with Alzheimer's disease, mild 1.2 10 cognitive impairment, and normal cognition. Psychogeriatrics, 2019, 19, 95-104. The role of hippocampus in the retrieval of autobiographical memories in patients with amnestic Mild 1.4 16 Cognitive Impairment due to Alzheimer's disease. Journal of Neuropsychology, 2020, 14, 46-68. 213 Imaging biomarkers in Alzheimer's disease., 2020, , 343-378. 1 Neuropsychiatric Correlates of Small Vessel Disease Progression in Incident Cognitive Decline: 214 Independent and Interactive Effects. Journal of Alzheimer's Disease, 2020, 73, 1053-1062. Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and 215 31 3.3 Molecular Imaging. Radiographics, 2020, 40, 200-222. Diagnosis of Rapidly Progressive Dementia in a Referral Center in Argentina. Alzheimer Disease and 1.3 Associated Disorders, 2020, 34, 54-58. Comorbid amyloidâ€Î² pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 217 0.8 6 2020, 16, 354-364. Prediction of poor clinical outcome in vascular cognitive impairment: TRACEâ€VCI study. Alzheimer's 2.4 and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12077. Sex differences in CSF biomarkers vary by Alzheimer disease stage and $\langle i \rangle$ APOE $\langle i \rangle$ $\hat{\mu}4$ genotype. 219 1.1 48 Neurology, 2020, 95, e2378-e2388. Microbleeds and Medial Temporal Atrophy Determine Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study. Journal of Alzheimer's Disease, 2020, 77, 1431-1442. Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year 221 2.7 10 follow-up. NeuroImage: Clinical, 2020, 27, 102310. Reproducibility of EEG functional connectivity in Alzheimer's disease. Alzheimer's Research and 6.2 Therapy, 2020, 12, 68.

#	Article	IF	CITATIONS
223	Behavioral psychological symptoms of dementia and functional connectivity changes: a network-based study. Neurobiology of Aging, 2020, 94, 196-206.	3.1	9
224	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	7.6	158
225	Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine, 2020, 9, 1919.	2.4	4
226	[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5875-5887.	7.9	14
227	Cerebellar dentate nucleus functional connectivity with cerebral cortex in Alzheimer's disease and memory: a seed-based approach. Neurobiology of Aging, 2020, 89, 32-40.	3.1	38
228	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. Journal of Alzheimer's Disease, 2020, 75, 751-765.	2.6	10
229	Cognitive profiles in adult-onset neuronal intranuclear inclusion disease: a case series from the memory clinic. Neurological Sciences, 2021, 42, 2487-2495.	1.9	8
230	Alterations of Brain Networks in Alzheimer's Disease and Mild Cognitive Impairment: A Resting State fMRI Study Based on a Population-specific Brain Template. Neuroscience, 2021, 452, 192-207.	2.3	20
231	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer's and Dementia, 2021, 17, 205-214.	0.8	17
232	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. European Radiology, 2021, 31, 666-673.	4.5	4
233	Management of the predementia stage of Alzheimer's disease, complicated with hypoactive delirium. Russian Neurological Journal, 2021, 25, 40-46.	0.3	0
234	Clinical utility of brain computed tomography in prediction of post-stroke delirium. Journal of Neural Transmission, 2021, 128, 207-213.	2.8	3
235	Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia. Current Alzheimer Research, 2021, 17, 893-903.	1.4	4
236	Transient Cognitive Impairment and White Matter Hyperintensities in Severely Depressed Older Patients Treated With Electroconvulsive Therapy. American Journal of Geriatric Psychiatry, 2021, 29, 1117-1128.	1.2	4
237	Evaluation of Sodium (²³ Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. In Vivo, 2021, 35, 429-435.	1.3	14
238	Modified cerebral small vessel disease score is associated with vascular cognitive impairment after lacunar stroke. Aging, 2021, 13, 9510-9521.	3.1	14
239	A survey on functional and cognitive assessment for diagnosing neurodegenerative disorders. Materials Today: Proceedings, 2021, , .	1.8	0
240	Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment. Scientific Reports, 2021, 11, 4010.	3.3	43

	CHATION	REPORT	
#	Article	IF	CITATIONS
241	Clonazepam-induced lichenoid drug eruption: a case report. BMC Psychiatry, 2021, 21, 125.	2.6	2
242	Bringing psychiatrists into the picture: Automated measurement of regional MRI brain volume in patients with suspected dementia. Australian and New Zealand Journal of Psychiatry, 2021, 55, 799-808.	2.3	1
243	Increase of blood-brain barrier leakage is related to cognitive decline in vascular mild cognitive impairment. BMC Neurology, 2021, 21, 159.	1.8	29
244	PSEN1 Compound Heterozygous Mutations Associated with Cerebral Amyloid Angiopathy and Cognitive Decline Phenotype. International Journal of Molecular Sciences, 2021, 22, 3870.	4.1	6
245	Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease. Scientific Reports, 2021, 11, 10343.	3.3	10
246	Distinctive Alterations of Functional Connectivity Strength between Vascular and Amnestic Mild Cognitive Impairment. Neural Plasticity, 2021, 2021, 1-8.	2.2	4
248	Molecular and Anatomical Imaging of Dementia With Lewy Bodies and Frontotemporal Lobar Degeneration. Seminars in Nuclear Medicine, 2021, 51, 264-274.	4.6	7
249	Memory for public events in amnestic mild cognitive impairment: The role of hippocampus and ventroâ€medial prefrontal cortex. Journal of Neuropsychology, 2022, 16, 131-148.	1.4	4
250	Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series. BMC Psychiatry, 2021, 21, 289.	2.6	1
251	Behavioral variations among vascular cognitive impairment subtypes – A comparative study. Applied Neuropsychology Adult, 2021, , 1-8.	1.2	4
252	Prediction of Subtle Cognitive Decline in Normal Aging: Added Value of Quantitative MRI and PET Imaging. Frontiers in Aging Neuroscience, 2021, 13, 664224.	3.4	0
253	Differences in Brain Morphology between Hydrocephalus Ex Vacuo and Idiopathic Normal Pressure Hydrocephalus. Psychiatry Investigation, 2021, 18, 628-635.	1.6	11
254	Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population. BMC Neurology, 2021, 21, 289.	1.8	9
255	Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer's disease. European Journal of Neurology, 2021, 28, 2980-2988.	3.3	6
256	Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. European Radiology, 2021, , 1.	4.5	1
257	Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment. Journal of Alzheimer's Disease, 2021, 82, 985-1000.	2.6	16
258	Neuroradiologic Evaluation of MRI in High-Contact Sports. Frontiers in Neurology, 2021, 12, 701948.	2.4	5
259	GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease. Seminars in Cell and Developmental Biology, 2021, 116, 146-159.	5.0	77

#	Article	IF	CITATIONS
260	Sarcopenia is independently associated with parietal atrophy in older adults. Experimental Gerontology, 2021, 151, 111402.	2.8	9
261	A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions. Neuroradiology, 2021, 63, 2035-2046.	2.2	6
262	Incidental findings of typical iNPH imaging signs in asymptomatic subjects with subclinical cognitive decline. Fluids and Barriers of the CNS, 2021, 18, 37.	5.0	10
263	VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly. , 2007, , 181-188.		13
264	Neurodegenerative Diseases: Alzheimer Disease (AD). , 2019, , 897-931.		2
266	Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 491-7.	1.9	259
267	Deep but Not Periventricular White Matter Disease Is a Marker for Frailty in Older Patients with Early Alzheimer's Disease. Advances in Geriatric Medicine and Research, 2019, 1, .	0.6	1
268	Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 191-198.	1.4	28
269	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment―(TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.	1.0	29
270	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Research Protocols, 2018, 7, e80.	1.0	3
271	Erken Evre Alzheimer Hastalığında İzlenen Ak Madde Hiperintensitelerinin Depresif Semptomlar ve Günlük Yaşam Aktiviteleri ile İlişkisi. Noropsikiyatri Arsivi, 2013, 50, 360-363.	0.7	2
272	Regional Beta Index of Electroencephalography May Differentiate Alzheimer's Disease from Depression. Psychiatry Investigation, 2017, 14, 708.	1.6	5
273	Manual Planimetry of the Medial Temporal Lobe Versus Automated Volumetry of the Hippocampus in the Diagnosis of Alzheimer's Disease. Cureus, 2016, 8, e544.	0.5	10
274	Assessment of Mild Cognitive Impairment in Elderly Subjects Using a Fully Automated Brain Segmentation Software. Investigative Magnetic Resonance Imaging, 2021, 25, 164.	0.4	2
275	Determinants of Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study in a Community-based Cohort. Current Alzheimer Research, 2021, 18, 482-491.	1.4	3
276	Medial Temporal Lobe Subregional Atrophy in Aging and Alzheimer's Disease: A Longitudinal Study. Frontiers in Aging Neuroscience, 2021, 13, 750154.	3.4	19
277	Neurodegenerative Disorders. , 2002, , 31-138.		0
278	16 MRI and the Differential Diagnosis of Dementia. , 2009, , 261-272.		0

#	Article	IF	CITATIONS
279	Automatic Morphological Analysis of Medial Temporal Lobe. The Open Nuclear Medicine Journal, 2010, 2, 31-39.	0.2	0
285	Cerebral perivascular spaces as an important diagnostic marker of cerebral small vessel disease and brain pathology. Journal of Education, Health and Sport, 2020, 10, 190.	0.1	0
286	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12098.	3.7	5
287	Structural Volume of Hippocampus and Alzheimer's Disease. Revista Da Associação Médica Brasileira, 2020, 66, 512-515.	0.7	9
288	Confluent White Matter in Progression to Alzheimer Dementia. Alzheimer Disease and Associated Disorders, 2021, 35, 8-13.	1.3	8
289	The Effect of Spinal Cord Injury on Beta-Amyloid Plaque Pathology in TgCRND8 Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 576-586.	1.4	2
290	The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale. Current Alzheimer Research, 2020, 17, 534-539.	1.4	6
291	Functional MR imaging in Alzheimer's disease during memory encoding. American Journal of Neuroradiology, 2000, 21, 1869-75.	2.4	162
292	Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2021, 121, 6.	0.7	31
293	The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation. Radiotherapy and Oncology, 2022, 168, 241-249.	0.6	11
294	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100141.	0.9	2
295	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	Ο
296	Correlation between Clinical Dementia Rating and brain neuroimaging metrics of Alzheimer's disease: An observational study from a tertiary care institute of Eastern India. Archives of Mental Health, 2022, 23, 56.	0.1	2
297	Personality Impact on Alzheimer's Disease — Signature and Vascular Imaging Markers: A PET-MRI Study. Journal of Alzheimer's Disease, 2022, 85, 1807-1817.	2.6	5
298	Qualitative and Quantitative Comparison of Hippocampal Volumetric Software Applications: Do All Roads Lead to Rome?. Biomedicines, 2022, 10, 432.	3.2	0
299	Safety and Usefulness of Lumbar Puncture for the Diagnosis and Management of Young-Onset Cognitive Disorders. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1
301	APOE4 and Confluent White Matter Hyperintensities Have a Synergistic Effect on Episodic Memory Impairment in Prodromal Dementia. Journal of Alzheimer's Disease, 2022, 87, 1103-1114.	2.6	5
302	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report. Frontiers in Neurology, 2022, 13, 839539.	2.4	6

#	Article	IF	CITATIONS
307	Alzheimer resemblance atrophy index, BrainAGE, and normal pressure hydrocephalus score in the prediction of subtle cognitive decline: added value compared to existing MR imaging markers. European Radiology, 2022, 32, 7833-7842.	4.5	4
309	Determining the Minimal Important Change of Everyday Functioning in Dementia. Neurology, 2022, 99, .	1.1	2
310	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. European Radiology, 2022, 32, 7789-7799.	4.5	3
311	Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods. Frontiers in Psychiatry, 0, 13, .	2.6	0
314	Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	6.2	4
315	Cognitive Reserve Modulates Brain Structure and Cortical Architecture in the Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 89, 811-824.	2.6	6
316	Are the inhibitory and faciliatory effects during retrieval of semantically related items present in amnestic mild cognitive impairment?. Journal of Neuropsychology, 0, , .	1.4	0
317	Brain atrophy pattern in patients with mild cognitive impairment: MRI study. Translational Neuroscience, 2022, 13, 335-348.	1.4	0
318	The possibilities of differential diagnosis of primary progressive aphasia. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 121.	0.7	0
319	Î2-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. Neurology, 2022, 99, .	1.1	11
320	Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country. Frontiers in Neurology, 0, 13, .	2.4	2
321	Radiological assessment of dementia: the Italian inter-society consensus for a practical and clinically oriented guide to image acquisition, evaluation, and reporting. Radiologia Medica, O, , .	7.7	5
322	Augmenting Magnetic Resonance Imaging withÂTabular Features forÂEnhanced andÂInterpretable Medial Temporal Lobe Atrophy Prediction. Lecture Notes in Computer Science, 2022, , 125-134.	1.3	0
324	Feasibility and usefulness of brain imaging in catatonia. Journal of Psychiatric Research, 2023, 157, 1-6.	3.1	3
325	Integrating Neuroimaging Measures in Nursing Research. Biological Research for Nursing, 2023, 25, 341-352.	1.9	1
326	Serum Cathepsin D Is a Potential Biomarker for Alzheimer's Disease Dementia and Cognitive Decline. Journal of Alzheimer's Disease, 2023, 91, 989-998.	2.6	1
327	Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study. Alzheimer's and Dementia, 2023, 19, 2298-2306.	0.8	3
328	Associations of carotid artery flow parameters with MRI markers of cerebral small vessel disease and patterns of brain atrophy. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106981.	1.6	2

#	Article	IF	CITATIONS
329	White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer's disease. PLoS ONE, 2023, 18, e0283790.	2.5	1
330	Episodic Memory in Amnestic Behavioral Frontotemporal Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 605-612.	2.2	0
331	Early predictors of dysphagia in ischaemic stroke patients. European Journal of Neurology, 2023, 30, 2324-2337.	3.3	1
332	Physical activity, biomarkers of brain pathologies and dementia risk: Results from the Memento clinical cohort. Alzheimer's and Dementia, 2023, 19, 5700-5718.	0.8	1
333	Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review. Alzheimer's and Dementia, 2023, 19, 5885-5904.	0.8	7
334	MR Imaging of Neurodegeneration. , 2023, , 169-181.		0
335	Preclinical Brain Network Abnormalities in Patients with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	0
336	Prediction of post-stroke cognitive impairment after acute ischemic stroke using machine learning. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
337	Fine-grained age-matching improves atrophy-based detection of mild cognitive impairment more than amyloid-negative reference subjects. NeuroImage: Clinical, 2023, 40, 103508.	2.7	0
338	Heterogeneity of Alzheimer's disease identified by neuropsychological test profiling. PLoS ONE, 2023, 18, e0292527.	2.5	0
340	Influence of cerebral blood flow on volumetric loss related to Alzheimer's disease. Dementia E Neuropsychologia, 0, 17, .	0.8	0
341	Automatic MRI volumetry in asymptomatic cases at risk for normal pressure hydrocephalus. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
342	Predicting amyloid-PET status in a memory clinic: The role of the novel antero-posterior index and visual rating scales. Journal of the Neurological Sciences, 2023, 455, 122806.	0.6	0
343	A three-dimensional deep learning model for inter-site harmonization of structural MR images of the brain: Extensive validation with a multicenter dataset. Heliyon, 2023, 9, e22647.	3.2	0
344	A systematic review of (semi-)automatic quality control of T1-weighted MRI scans. Neuroradiology, 0, ,	2.2	0
345	Mesial temporal atrophy in preoperative MRI rather than steep Trendelenburg position is associated with postoperative delirium in patients undergoing a major urologic surgery. International Urology and Nephrology, 0, , .	1.4	0
346	Age of onset predicted by Aβ profiling in a novel PSEN1 (I180F) mutation. Neuroscience Letters, 2024, 820, 137591.	2.1	0
347	Data-driven analysis of regional brain metabolism in behavioral frontotemporal dementia and late-onset primary psychiatric diseases with frontal lobe syndrome: A PET/MRI study. Neurobiology of Aging, 2024, 137, 47-54.	3.1	Ο

#	Article	IF	CITATIONS
348	The clinical and neuroimaging differences between vascular parkinsonism and Parkinson's disease: a case-control study. BMC Neurology, 2024, 24, .	1.8	0
350	The Association Between Positive Amyloid-PET and Cognitive Decline Is Not Always Supportive of Alzheimer's Disease: Suggestions from a Case Report. Journal of Alzheimer's Disease Reports, 2024, 8, 281-288.	2.2	0
351	Visual associative learning to detect early episodic memory deficits and distinguish Alzheimer's disease from other types of dementia. Journal of the International Neuropsychological Society, 0, , 1-10.	1.8	0
352	Dual-task turn velocity – a novel digital biomarker for mild cognitive impairment and dementia. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0